Generic Name and Formulations:
Anagrelide (as HCl) 0.5mg; caps.
Shire US, Inc.
Indications for AGRYLIN:
Treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce elevated platelet count and the risk of thrombosis and to improve symptoms.
≥16yrs: Initially 0.5mg four times daily or 1mg twice daily for ≥1 week. May increase dose by 0.5mg/day weekly to maintain normal platelet count; max 10mg/day or 2.5mg/dose. Moderate hepatic impairment: initially 0.5mg/daily.
<7yrs: not established. 7–16yrs: Initially 0.5mg daily. May increase dose by 0.5mg/day weekly to maintain normal platelet count; max 10mg/day or 2.5mg/dose.
Congenital long QT syndrome, acquired QTc prolongation, hypokalemia: not recommended. Obtain baseline cardiovascular exam and monitor during treatment. Monitor for QTc prolongation and other cardiovascular events in those with hepatic impairment. Heart failure, bradyarrhythmias, electrolyte abnormalities; consider periodic ECG monitoring. Evaluate for underlying cardiopulmonary disease prior to initiation and during therapy. Discontinue and evaluate if pulmonary toxicity is suspected. Monitor CBCs, electrolytes, renal and liver function before initiating and during therapy. Obtain platelet counts every 2 days during 1st week of treatment, then weekly until maintenance dose reached. Cessation may cause platelet count to rise within 4 days. Severe hepatic impairment: avoid. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).
Platelet-reducing agent (PDE3 inhibitor).
Concomitant drugs that can prolong the QT interval (eg, chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, amiodarone, disopyramide, procainamide, pimozide), inotropes, other PDE3 inhibitors (eg, cilostazol, milrinone): not recommended. Concomitant anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, SSRIs; monitor for bleeding. Potentiated by fluvoxamine, ciprofloxacin or other CYP1A2 inhibitors. Antagonized by omeprazole or other CYP1A2 inducers; may need to adjust dose. May affect CYP1A2 substrates (eg, theophylline, fluvoxamine, ondansetron).
Headache, palpitations, diarrhea, asthenia, edema, nausea, abdominal pain, dizziness, pain, dyspnea, flatulence, vomiting, fever, rash, chest pain, anorexia, tachycardia, malaise, cough, paresthesia, back pain, pruritus, dyspepsia; cardiovascular effects (eg, torsades de pointes, ventricular tachycardia, CHF), pulmonary hypertension, interstitial lung disease.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Whole Genome Sequencing Use in Predicting TB Resistance
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Interferon Alfa May Decrease the Incidence of Chronic HCV Infection
- Predicative Factors for Relapse in Adult Bacterial Osteomyelitis
- Supply Updates Announced for Recombivax HBV Vaccines
- Point-of-Care Testing Methods Compared for Influenza Detection
- Success With DAA for Hepatitis C Prior to Stem Cell Transplant